Vivus - Qsymia Sales Point To Inability To Grow In Space

Vivus - Qsymia Sales Point To Inability To Grow In Space


Vivus investors seem to want to hold onto the faith that somehow the anti-obesity drug Qsymia will suddenly see a shift to the positive that can turn around the company. The reality is that Vivus has cut marketing expenses as far as it can, and that insurance companies are dropping coverage, leaving Vivus at an interesting crossroads.



from Biotech News